Page 6 - Randomized Phase News Today

The second pivotal Phase 3 trial reported NOV03 consistently met primary endpoints for signs and symptoms of DED associated with meibomian gland dysfunction.

Phase 1b/2 trial in lead KRAS-mutated metastatic colorectal cancer (mCRC) program continues to show our lead candidate onvansertib demonstrates an objective...

The positive CHMP opinion for upadacitinib is based on results from two induction studies and one maintenance study1-4 Crohns disease is a chronic, systemic...

L’AFP est une agence d’information globale, assurant une couverture rapide, complète et vérifiée des événements de l’actualité comme des thèmes qui façonnent notre quotidien. Avec un réseau de journalistes sans égal, déployé sur 151 pays, l'AFP est en outre un leader mondial de l’investigation nu...

CHMP determined CyclASol is eligible for a centralised procedure Novaliq has submitted a Letter of intent to file a Marketing Authorisation Application (MAA) in July 2023 Novaliq, a biopharmaceutical

Two global Phase 3 trials in adult CLL patients demonstrated superior efficacy for BRUKINSA (zanubrutinib) in first-line and relapsed/refractory treatment settings BRUKINSA is the only BTKi to demonstrate

CTIM-76 nominated as Claudin 6 x CD3 bispecific antibody clinical candidate Encouraging endometrial and breast cancer data in ongoing ONA-XR Phase 2 trials, with additional data updates expected in... | January 4, 2023

/PRNewswire/ --Research findings being presented during the 64th American Society of Hematology (ASH) Annual Meeting and Exposition challenge standard...

/PRNewswire/ -- AbbVie (NYSE: ABBV) will present results from nearly 65 company and partner abstracts across 8 types of cancer during the upcoming American...

/PRNewswire/ -- AbbVie (NYSE: ABBV) will present results from nearly 65 company and partner abstracts across 8 types of cancer during the upcoming American...